Supercharge Your Innovation With Domain-Expert AI Agents!

Application of dovitinib in anti-mycobacterium tuberculosis drugs

A technology of mycobacterium tuberculosis and mycobacteria, applied in the field of bioengineering, can solve the problem that the success rate of severe multidrug-resistant tuberculosis treatment is less than 25%, achieve enhanced cell killing of tuberculosis, good development value, and high safety Effect

Pending Publication Date: 2019-09-06
SHENZHEN UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The global average treatment success rate for the MDR-TB cohort is 50%, compared to less than 25% for severe multidrug-resistant tuberculosis (XDR-TB)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dovitinib in anti-mycobacterium tuberculosis drugs
  • Application of dovitinib in anti-mycobacterium tuberculosis drugs
  • Application of dovitinib in anti-mycobacterium tuberculosis drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] 1. Differentiation of U937 macrophages (No. BNCC100967): Suspended U937 macrophages were cultured in RPMI-1640 medium containing 10% FBS, and placed at a temperature of 37°C, containing 5% CO 2 Cultured in a cell incubator, added PMA with a final concentration of 20ng / ml, cultured overnight, differentiated into macrophages, washed twice with PBS, digested with trypsin, resuspended, added to a 96-well cell culture plate , so that the number of cells per well is 1x104;

[0023] 2. Determination of cell survival rate: After the above-mentioned U937 macrophages were cultured for 24 hours, different concentrations of drugs were added to make the final drug concentrations 100uM, 10uM, and 1uM. The experiment was repeated three times for each concentration, and DMSO was used as a parallel control experiment. , the same volume of DMSO as the drug was added to the control group, and the experiments were repeated three times. After 48 hours, 10ul of WST-1 solution was added to ea...

Embodiment 2

[0029] 1. Differentiation of U937 macrophages: Suspended U937 macrophages were cultured in RPMI-1640 medium containing 10% FBS, and placed in a temperature of 37 ° C, containing 5% CO 2 Cultured in a cell incubator, added PMA with a final concentration of 20ng / ml, cultured overnight, differentiated into macrophages, washed twice with PBS, digested with trypsin, resuspended, added to a 96-well cell culture plate , so that the number of cells per well is 1x104;

[0030] 2. Determination of intracellular bactericidal activity: After the above-mentioned U937 macrophages were cultured for 24 hours, dovitinib was added to make the final concentration 10uM. The experiment was repeated 3 times for each concentration, and DMSO was used as a parallel control experiment. In the control group, dovitinib was added DMSO with the same volume as the drug was repeated 3 times. After 4 hours, the medium was sucked off, washed twice with PBS, fresh medium was added for 72 hours, and the lysate w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of dovitinib in anti-mycobacterium tuberculosis drugs. Dovitinib is an oral active small-molecular tyrosine kinase inhibitor and has strong inhibitory activityagainst various RTKs participating in tumor growth and angiogenesis; researches find out that dovitinib has anti-tuberculous effect and good development value; the application of dovitinib in the anti-mycobacterium tuberculosis drugs and an obvious anti-mycobacterium tuberculosis effect of dovitinib are disclosed for the first time.

Description

technical field [0001] The invention relates to the technical field of bioengineering, in particular to the application of dovitinib in anti-tuberculosis mycobacterium drugs. Background technique [0002] In 2014, WHO estimated that there were 480,000 new MDR-TB cases worldwide, of which only about 26% were detected and reported. The global average treatment success rate for the MDR-TB cohort is 50%, compared with less than 25% for severe multidrug-resistant tuberculosis (XDR-TB). Therefore, research and development of effective new drugs / programs for the treatment of tuberculosis in order to improve the treatment effect, shorten the course of treatment, reduce toxic side effects, and overcome clinical drug resistance are major issues and research hotspots in the prevention and control of tuberculosis. [0003] Dovitinib is an orally active small molecule tyrosine kinase inhibitor with potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61P31/06
CPCA61K31/496A61P31/06
Inventor 蔡毅陈心春欧阳琪
Owner SHENZHEN UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com